Market Overview

UPDATE: Bank of America Merrill Lynch Reiterates Neutral Rating, Lowers PO on Boston Scientific

Related BSX
Early Global News: Judge Dismisses Yelp Lawsuit, Boston Scientific Recall, Brazil Suing BHP & Vale
Boston Scientific Receives CE Mark For Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device
Do Not Strike Stryker Out (Seeking Alpha)

In a report published Friday, Bank of America Merrill Lynch reiterated its Neutral rating on Boston Scientific (NYSE: BSX), but lowered its price objective from $8.50 to $6.30.

BofA Merrill Lynch noted, “In order to be more bullish on BSX, we need more conviction that ASP declines in BSX's core drug-eluting stent market will moderate and the Promus Element stent can be successful in the U.S. in order to allow for operating leverage, and we need more conviction that BSX can grow. If we became more convinced that operating leverage will materialize, it would make it much easier to call BSX cheap and to argue that a positive risk reward exists while we wait for management's plan to play out.”

Boston Scientific closed on Thursday at $5.66.

Latest Ratings for BSX

Nov 2015CitigroupInitiates Coverage onBuy
Oct 2015BarclaysMaintainsOverweight
Oct 2015Raymond JamesDowngradesOutperformStrong Buy

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Price Target Analyst Ratings


Related Articles (BSX)

Get Benzinga's Newsletters